Bufab Group
PRESS RELEASE, Värnamo March 25, 2021
Bufab’s Annual Report and Sustainability Report for 2020 is now available on the Group’s website www.bufab.com.
For further information, please contact:
Marcus Andersson, CFO, Bufab Group, telephone: +46 370 69 69 66
This information is such that Bufab AB (publ) is obliged to disclose in accordance with the EU’s Market Abuse Regulation. The information was submitted for publication by the aforementioned contacts on March 25, 2021 at 07:30 a.m. CET.
About Bufab
Bufab AB (publ), Corporate Registration Number 556685-6240, is a trading company that offers its customers a full-service solution as Supply Chain Partner for sourcing, quality control and logistics for C-Parts (screws, nuts, etc.). Bufab’s Global Parts ProductivityTM customer offering aims to improve productivity in the customers’ value chain for C-Parts.
Bufab was founded in 1977 in Småland and is an international company with operations in 28 countries. The head office is located in Värnamo, Sweden, and Bufab has about 1,300 employees. Bufab’s net sales for 2020 amounted to SEK 4.8 billion and the operating margin was 10.1 percent. The Bufab share is listed on Nasdaq Stockholm, under the ticker "BUFAB". Please visit www.bufab.com for more information.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
FLSmidth A/S9.7.2025 07:30:53 CEST | Press release
Transactions under share buy-back programme
Fingerprint Cards AB8.7.2025 22:20:54 CEST | Press release
Postponement of Reverse Share Split in Fingerprint Cards AB (publ) due to technical reasons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom